Charles Naltet

6.3k total citations
44 papers, 450 citations indexed

About

Charles Naltet is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Charles Naltet has authored 44 papers receiving a total of 450 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 30 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Charles Naltet's work include Lung Cancer Treatments and Mutations (26 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Lung Cancer Research Studies (15 papers). Charles Naltet is often cited by papers focused on Lung Cancer Treatments and Mutations (26 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Lung Cancer Research Studies (15 papers). Charles Naltet collaborates with scholars based in France, Spain and United States. Charles Naltet's co-authors include Stéphanie Corgnac, Maria Kfoury, Marie Boutet, Fathia Mami‐Chouaib, Benjamin Besse, David Planchard, Pernelle Lavaud, Laura Mezquita, Solenn Brosseau and Gérard Zalcman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and CHEST Journal.

In The Last Decade

Charles Naltet

38 papers receiving 449 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles Naltet France 11 332 226 120 65 41 44 450
Jinyan Yang China 8 124 0.4× 133 0.6× 129 1.1× 151 2.3× 109 2.7× 11 341
Jinghui Wang China 11 208 0.6× 174 0.8× 54 0.5× 113 1.7× 64 1.6× 57 441
Xixi Xie China 10 194 0.6× 201 0.9× 183 1.5× 236 3.6× 163 4.0× 12 493
José Carlos Benítez Spain 8 159 0.5× 94 0.4× 34 0.3× 54 0.8× 46 1.1× 39 301
Xiao Zhao China 9 202 0.6× 130 0.6× 67 0.6× 84 1.3× 41 1.0× 29 323
Arianna Citti Italy 8 131 0.4× 55 0.2× 115 1.0× 115 1.8× 52 1.3× 8 319
Elsa M. Li-Ning-Tapia United States 5 129 0.4× 146 0.6× 43 0.4× 78 1.2× 97 2.4× 6 313
Masatoshi Kanayama Japan 11 245 0.7× 158 0.7× 69 0.6× 35 0.5× 29 0.7× 49 351
Jubrail Dahabreh Greece 12 348 1.0× 191 0.8× 274 2.3× 159 2.4× 49 1.2× 28 615
Eric Shuffle United States 6 123 0.4× 172 0.8× 33 0.3× 105 1.6× 46 1.1× 11 373

Countries citing papers authored by Charles Naltet

Since Specialization
Citations

This map shows the geographic impact of Charles Naltet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Naltet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Naltet more than expected).

Fields of papers citing papers by Charles Naltet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Naltet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Naltet. The network helps show where Charles Naltet may publish in the future.

Co-authorship network of co-authors of Charles Naltet

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Naltet. A scholar is included among the top collaborators of Charles Naltet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Naltet. Charles Naltet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goldman, Jonathan W., Christophe Dooms, Komal Jhaveri, et al.. (2024). Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial. Clinical Lung Cancer. 26(3). 191–200.e1. 1 indexed citations
2.
Mennecier, B., Jonathan Khalifa, R. Descourt, et al.. (2024). Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study. BMC Cancer. 24(1). 421–421. 2 indexed citations
3.
4.
Tagliamento, Marco, Édouard Auclin, Mihaela Aldea, et al.. (2023). Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. European Journal of Cancer. 182. 107–114. 25 indexed citations
5.
Mercier, Olaf, Antonin Lévy, Angela Botticella, et al.. (2023). Outcomes of extended resection for locally advanced thymic malignancies. Respiratory Medicine and Research. 83. 101009–101009.
6.
Canellas, Anthony, Charles Naltet, Marie Wislez, et al.. (2023). Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control Study. Cancers. 15(18). 4593–4593. 4 indexed citations
7.
Riudavets, Mariona, Damien Vasseur, Édouard Auclin, et al.. (2022). Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer. Clinical Lung Cancer. 23(6). e377–e383. 1 indexed citations
8.
Fallet, Vincent, Guido Ahle, Jennifer Arrondeau, et al.. (2022). Troubles du système nerveux central sous lorlatinib : comment les détecter et les gérer en pratique ?. Bulletin du Cancer. 109(4). 477–490.
9.
Oulhen, Marianne, Patrycja Pawlikowska, Genny Buson, et al.. (2021). Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. npj Precision Oncology. 5(1). 67–67. 17 indexed citations
10.
Aldea, Mihaela, Claudia Parisi, Luigi Cerbone, et al.. (2021). 1344P Molecular features of young cannabis smokers with advanced non-small cell lung cancer (aNSCLC). Annals of Oncology. 32. S1024–S1025. 3 indexed citations
11.
12.
Ferrara, Roberto, Francesco Facchinetti, Giuseppina Calareso, et al.. (2020). 1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts). Annals of Oncology. 31. S826–S826. 7 indexed citations
13.
Besse, Benjamin, Julien Adam, Nathalie Cozic, et al.. (2020). 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial. Annals of Oncology. 31. S794–S795. 74 indexed citations
14.
Lévy, Antonin, J. Doyen, Angela Botticella, et al.. (2020). Place de l’immunothérapie dans le cancer bronchique non à petites cellules localement avancé. Cancer/Radiothérapie. 24(1). 67–72. 3 indexed citations
15.
Riudavets, Mariona, Caroline Caramella, Pauline Pradère, et al.. (2020). Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non–small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report. Clinical Lung Cancer. 22(2). e215–e219. 5 indexed citations
16.
Géraud, Arthur, Laura Mezquita, Édouard Auclin, et al.. (2020). Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. Cancers. 12(12). 3758–3758. 3 indexed citations
17.
Géraud, Arthur, Laura Mezquita, Édouard Auclin, et al.. (2019). MA21.09 Tyrosine Kinase Inhibitors' Plasma Concentration and Oncogene-Addicted Advanced Non-Small Lung Cancer (aNSCLC) Resistance. Journal of Thoracic Oncology. 14(10). S337–S338. 1 indexed citations
18.
Flippot, Ronan, Pamela Biondani, Édouard Auclin, et al.. (2019). Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. Journal of Thoracic Oncology. 14(8). 1400–1407. 22 indexed citations
19.
Brosseau, Solenn, V. Gounant, Charles Naltet, et al.. (2017). Lazarus Syndrome With Crizotinib in a Non–Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation. Clinical Lung Cancer. 19(1). e57–e61. 4 indexed citations
20.
Gounant, V., Solenn Brosseau, Charles Naltet, et al.. (2016). Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. Lung Cancer. 99. 162–165. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jinyan Yang Breakdown of academic impact, for papers by Jinghui Wang Breakdown of academic impact, for papers by Xixi Xie Breakdown of academic impact, for papers by José Carlos Benítez Breakdown of academic impact, for papers by Xiao Zhao Breakdown of academic impact, for papers by Arianna Citti Breakdown of academic impact, for papers by Elsa M. Li-Ning-Tapia Breakdown of academic impact, for papers by Masatoshi Kanayama Breakdown of academic impact, for papers by Jubrail Dahabreh Breakdown of academic impact, for papers by Eric Shuffle
Rankless by CCL
2026